1. Home
  2. PBBK vs SKYE Comparison

PBBK vs SKYE Comparison

Compare PBBK & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PB Bankshares Inc.

PBBK

PB Bankshares Inc.

HOLD

Current Price

$22.78

Market Cap

53.5M

Sector

Finance

ML Signal

HOLD

Logo Skye Bioscience Inc.

SKYE

Skye Bioscience Inc.

HOLD

Current Price

$1.00

Market Cap

44.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PBBK
SKYE
Founded
1919
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
53.5M
44.9M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
PBBK
SKYE
Price
$22.78
$1.00
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$14.75
AVG Volume (30 Days)
9.3K
249.9K
Earning Date
10-23-2025
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
53.39
N/A
EPS
0.98
N/A
Revenue
$13,918,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$22.75
N/A
Revenue Growth
17.20
N/A
52 Week Low
$14.16
$1.02
52 Week High
$22.92
$5.75

Technical Indicators

Market Signals
Indicator
PBBK
SKYE
Relative Strength Index (RSI) 70.53 34.07
Support Level $21.40 $1.04
Resistance Level $22.92 $1.27
Average True Range (ATR) 0.43 0.10
MACD 0.05 0.01
Stochastic Oscillator 91.86 2.90

Price Performance

Historical Comparison
PBBK
SKYE

About PBBK PB Bankshares Inc.

PB Bankshares Inc follows a community bank model and provides multiple services to individuals and small to midsize businesses. Its business consists of attracting retail and commercial deposits from the general public in its market area and investing those deposits, together with funds generated from operations and borrowings, in commercial real estate loans, commercial and industrial loans, construction, home equity lines of credit and to a lesser extent, one- to four-family residential real estate loans and consumer loans.

About SKYE Skye Bioscience Inc.

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Share on Social Networks: